Anti-Proliferative Activity of Butenyl Isothiocyanate Against Colon Cancer Cell Line

Background: Colorectal cancer (CRC) is the third most common malignancy in both men and women. Rectal cancer and colon cancer are frequently considered to be the same condition due to their shared characteristics. Polyps in the colon are the first sign of the disease and can develop into a malignant tumor. Patients with colon cancer often die of tumor recurrence and metastasis. Butyl isothiocyanate belongs to the isothiocyanate family, which has more attention since they have a lot of biological activity. Additionally, acetylsalicylic acid the non-steroidal anti-inflammatory drug significantly lowers the antiproliferative activity of cancer. Objective: To identify the anti-proliferative activity of butenyl isothiocyanate, acetylsalicylic acid and their combination against colon cancer cell line. In addition to identify the molecular mechanism evaluation of butenyl isothiocyanate by measuring vascular endothelial growth factor (VEGF) gene expression. Methods: Butenyl isothiocyanate and acetylsalicylic acid antiproliferative activity against the CL40 cell line was determined using the (4,5-Dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) test. Butenyl isothiocyanate gene expression levels were studied quantitatively using real-time polymerase chain reaction. Results: Butenyl isothiocyanate, acetylsalicylic acid, and their combination demonstrated dose-dependent significant suppression of proliferation of the colon cancer cell line CL40 (P <0.001). Furthermore, butenyl isothiocyanate showed a fold diminishing in VEGF gene expression of 35.83 % (P <0.001). Conclusion: Butenyl isothiocyanate, acetylsalicylic acid and their combination exhibited a significant antiproliferative effect. Furthermore, butenyl isothiocyanate\'s molecular mechanism of action was demonstrated to be the down-regulation of VEGF gene expression. Keywords: VEGF, antiproliferation, Butenyl isothiocyanate, Acetylsalicylic acid, MTT, CL-40, colon cancer, gene expression Citation: Mohamed SJ, Sahib HB. Anti-proliferative activity of butenyl isothiocyanate against colon cancer cell line. Iraqi JMS. 2025; 23(1): 64-74. doi: 10.22578/IJMS.23.1.8

Authors

Publication Details

Journal
Iraqi journal of Medical Sciences
Published
2025-06-30
DOI
https://doi.org/10.22578/ijms.23.1.8
Primary Topic
Genomics, phytochemicals, and oxidative stress
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anti-Proliferative Activity of Butenyl Isothiocyanate Against Colon Cancer Cell Line

Hayder B. Sahib, Shahad Mohamed
Iraqi journal of Medical Sciences
Genomics, phytochemicals, and oxidative stress
article

Anti-Proliferative Activity of Butenyl Isothiocyanate Against Colon Cancer Cell Line

Hayder B. Sahib, Shahad Mohamed
article en

Abstract

Background: Colorectal cancer (CRC) is the third most common malignancy in both men and women. Rectal cancer and colon cancer are frequently considered to be the same condition due to their shared characteristics. Polyps in the colon are the first sign of the disease and can develop into a malignant tumor. Patients with colon cancer often die of tumor recurrence and metastasis. Butyl isothiocyanate belongs to the isothiocyanate family, which has more attention since they have a lot of biological activity. Additionally, acetylsalicylic acid the non-steroidal anti-inflammatory drug significantly lowers the antiproliferative activity of cancer. Objective: To identify the anti-proliferative activity of butenyl isothiocyanate, acetylsalicylic acid and their combination against colon cancer cell line. In addition to identify the molecular mechanism evaluation of butenyl isothiocyanate by measuring vascular endothelial growth factor (VEGF) gene expression. Methods: Butenyl isothiocyanate and acetylsalicylic acid antiproliferative activity against the CL40 cell line was determined using the (4,5-Dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) test. Butenyl isothiocyanate gene expression levels were studied quantitatively using real-time polymerase chain reaction. Results: Butenyl isothiocyanate, acetylsalicylic acid, and their combination demonstrated dose-dependent significant suppression of proliferation of the colon cancer cell line CL40 (P <0.001). Furthermore, butenyl isothiocyanate showed a fold diminishing in VEGF gene expression of 35.83 % (P <0.001). Conclusion: Butenyl isothiocyanate, acetylsalicylic acid and their combination exhibited a significant antiproliferative effect. Furthermore, butenyl isothiocyanate\'s molecular mechanism of action was demonstrated to be the down-regulation of VEGF gene expression. Keywords: VEGF, antiproliferation, Butenyl isothiocyanate, Acetylsalicylic acid, MTT, CL-40, colon cancer, gene expression Citation: Mohamed SJ, Sahib HB. Anti-proliferative activity of butenyl isothiocyanate against colon cancer cell line. Iraqi JMS. 2025; 23(1): 64-74. doi: 10.22578/IJMS.23.1.8

Iraqi journal of Medical SciencesVol. 23(1)
Good health and well-being
Openalex Percentile: Top 33%
Genomics, phytochemicals, and oxidative stress
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Anti-Proliferative Activity of Butenyl Isothiocyanate Against Colon Cancer Cell Line — Hayder B. Sahib, Shahad Mohamed · Iraqi journal of Medical Sciences (2025) | TGRS Research Map | TGRS